First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

JSON

Di Giacomo AM, Santangelo F, Amato G, Simonetti E, Graham J, Lahn MMF, Di Conza G, Hammett T, Zorrilla R, Durini M, Tan Z, Tadepally L, Brodin P, Occhipinti M, Simonelli M, Carlo-Stella C, Santoro A, Spiliopoulou P, Evans TRJ, Maio M

J Clin Oncol 41 (16_suppl) 3110-3110 [2023-06-01; online 2023-06-01]

DOI 10.1200/jco.2023.41.16_suppl.3110

Crossref 10.1200/jco.2023.41.16_suppl.3110